Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Lavalle-González FJ, et al. Among authors: januszewicz a. Diabetologia. 2013 Dec;56(12):2582-92. doi: 10.1007/s00125-013-3039-1. Epub 2013 Sep 13. Diabetologia. 2013. PMID: 24026211 Free PMC article. Clinical Trial.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H. Ritz E, et al. Among authors: januszewicz a. Diabetologia. 2010 Jan;53(1):49-57. doi: 10.1007/s00125-009-1577-3. Epub 2009 Oct 30. Diabetologia. 2010. PMID: 19876613 Free PMC article. Clinical Trial.
Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
Menne J, Izzo JL Jr, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H; ROADMAP investigators. Menne J, et al. Among authors: januszewicz a. J Hypertens. 2012 Apr;30(4):811-8; discussion 818. doi: 10.1097/HJH.0b013e328351856d. J Hypertens. 2012. PMID: 22418908 Clinical Trial.
Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
Januszewicz A, Ritz E, Viberti G, Mimran A, Rabelink AJ, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Haller H. Januszewicz A, et al. J Hum Hypertens. 2011 Nov;25(11):679-85. doi: 10.1038/jhh.2010.111. Epub 2010 Dec 9. J Hum Hypertens. 2011. PMID: 21150933 Clinical Trial.
Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease.
Prejbisz A, Sellin L, Szwench-Pietrasz E, Woznowski M, Michałowska I, Blondin D, Sajnaga D, Epplen JT, Litwin M, Dekomien G, Januszewicz M, Helmchen U, Matuszkiewicz-Rowińska J, Adamczak M, Więcek A, Januszewicz A, Rump LC. Prejbisz A, et al. Among authors: januszewicz a, januszewicz m. Kidney Int. 2015 Jul;88(1):160-6. doi: 10.1038/ki.2015.2. Epub 2015 Feb 11. Kidney Int. 2015. PMID: 25671765 Free article.
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder RE, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, McClure CK, Kirtane AJ; RADIANCE-HTN investigators. Azizi M, et al. Lancet. 2021 Jun 26;397(10293):2476-2486. doi: 10.1016/S0140-6736(21)00788-1. Epub 2021 May 16. Lancet. 2021. PMID: 34010611 Clinical Trial.
Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms.
Heinrich DA, Adolf C, Rump LC, Quack I, Quinkler M, Hahner S, Januszewicz A, Seufert J, Willenberg HS, Nirschl N, Sturm L, Beuschlein F, Reincke M. Heinrich DA, et al. Among authors: januszewicz a. Eur J Endocrinol. 2018 Jun;178(6):605-611. doi: 10.1530/EJE-17-0978. Epub 2018 Apr 10. Eur J Endocrinol. 2018. PMID: 29636356
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A. Haller H, et al. Among authors: januszewicz a. J Hypertens. 2006 Feb;24(2):403-8. doi: 10.1097/01.hjh.0000202820.56201.e6. J Hypertens. 2006. PMID: 16508590 Clinical Trial.
334 results